Results 11 to 20 of about 10,303 (292)

Eficacia y seguridad de la inmunoterapia anti-PD-1/PD-L1 en cáncer de endometrio avanzado: una revisión sistemática

open access: yesOncología
Introducción: El cáncer de endometrio es la neoplasia maligna más frecuente del tracto genital femenino en países desarrollados. El tratamiento estándar de primera línea en estadios avanzados es la quimioterapia basada en platino.
Silvia Vázquez-Gómez   +1 more
doaj   +2 more sources

Inmunoterapia en cáncer

open access: yesActa Médica Colombiana
La inmunoterapia es un tratamiento donde la estimulación del sistema inmune permite al organismo reaccionar contra ciertos tumores, mostrando amplios beneficios en pacientes con cáncer, donde los fármacos que se emplean favorecen la recuperación de funciones alteradas del sistema inmunológico, no obstante, una variedad de neoplasias tanto solidas como ...
Luis Felipe Cárdenas-Losada   +3 more
openaire   +2 more sources

Unidades de inmunoterapia

open access: diamondAllergologia et Immunopathologia, 2003

openalex   +2 more sources

Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. [PDF]

open access: yesCancer Med
Elevated serum ferritin levels before treatment with azacytidine are associated with lower response rates and shorter survival in patients with myelodysplastic syndromes. This study supports the early identification of transfusion‐related iron overload to improve treatment planning.
Carrasco GM   +8 more
europepmc   +2 more sources

Immunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An anti-inflammatory agent-sparing approach. [PDF]

open access: yesVet Dermatol
Background – Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD). Objective – To assess the anti‐inflammatory agent‐sparing effect over 1 year of immunotherapy using pullulan‐conjugated recombinant Der f 2 (rDf2‐P). Conclusions and Clinical Relevance – Der f 2‐P immunotherapy can lead to a rapid reduction in anti‐
Nagata M   +7 more
europepmc   +2 more sources

RF-SARS-CoV-2 Vaccination and Immunotherapy in Dermatology. [PDF]

open access: goldActas Dermosifiliogr, 2022
Rodríguez-Villa Lario A   +2 more
europepmc   +2 more sources

Melanoma y tratamiento con inmunoterapia

open access: yesRECIAMUC
Uno de los tipos de cáncer más frecuentes en todo el mundo es el cáncer de piel. Entre ellos, el melanoma, a pesar de no ser el más frecuente es el más agresivo, crece más rápido y tiene mayor probabilidad de propagarse sin un diagnóstico o tratamiento temprano.
Luigina Elizabeth Benalcázar Vásquez   +3 more
openaire   +2 more sources

Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity

open access: yesVeterinary Dermatology, Volume 34, Issue 6, Page 532-542, December 2023., 2023
Background – Hymenoptera envenomation occurs frequently in people and dogs and can trigger anaphylaxis. Venom immunotherapy (VIT) is the only preventative treatment for Hymenoptera hypersensitivity and is indicated for people with severe adverse reactions to insect stings. Rush VIT is an accelerated VIT induction schedule performed in people.
Alexandra Moore   +4 more
wiley   +1 more source

The safety of rush immunotherapy in the management of canine atopic dermatitis—230 cases

open access: yesVeterinary Dermatology, Volume 34, Issue 5, Page 385-392, October 2023., 2023
Background – The duration of the induction phase of allergen‐specific immunotherapy conventionally is a period of several weeks, during which the volume of an allergen solution, administered by injection, is gradually increased until the maintenance dose is reached.
Tamara Weitzer, Ralf Mueller
wiley   +1 more source

Toxicity evaluation of ConvitVax breast cancer immunotherapy

open access: yesScientific Reports, 2021
ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin.
María A. Duarte C.   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy